Ramsay Santé delivers revenue growth of 2.9%
European healthcare provider Ramsay Santé generated first-quarter revenue of €1.2 billion after expanding its volume of day medicine admissions in France.
Todas as matérias desta categoria, das mais recentes às mais antigas.
European healthcare provider Ramsay Santé generated first-quarter revenue of €1.2 billion after expanding its volume of day medicine admissions in France.
Mayne Pharma (ASX:MYX) has entered into a binding agreement to sell its wholly owned subsidiary Mayne Pharma International to Evaris Pharma for $55.5 million in upfront cash.
AVITA Medical (ASX:AVH) reported a 53% year-over-year increase in third-quarter total revenue to US$26.1 million.
Medical software firm Heidi Health announced plans to reduce its workforce by 18% following the departures of chief technology officer Yu Liu and CFO Waleed Mussa.
Neuren Pharmaceuticals (ASX:NEU) upgraded its full-year 2026 financial guidance after partner Acadia Pharmaceuticals (NASDAQ:ACAD) reported a 39% surge in third-quarter DAYBUE net sales.
Arovella Therapeutics (ASX:ALA) appointed Dr Nicole Van Der Weerden as its Acting CEO.
Radiopharm Theranostics (ASX:RAD) reached an agreement with the US Food and Drug Administration on the design of a single pivotal Phase 3 imaging trial for its RAD101 diagnostic molecule.
Island Pharmaceuticals (ASX:ILA) has commenced scheduled surgical preparations for 22 non-human primates at the United States Army Medical Research Institute of Infectious Diseases.
Regenerative medicine company Orthocell (ASX:OCC) announced that its partner Marine Biomedical received US FDA 510(k) clearance for PearlBone.
Percheron Therapeutics (ASX:PER) received FDA approval for an investigator-sponsored trial evaluating HMBD-002 in combination with venetoclax and azacitidine for acute myeloid leukaemia.
Neurizon Therapeutics (ASX:NUZ) has secured firm commitments to raise $4.3 million through a placement of 63.2 million shares at $0.068 per share.
Orthocell (ASX:OCC) reported $279,000 in U.S. revenue for October after selling 92 units of its nerve repair product, Remplir.
Tem um segundo para um cookie? 🍪Os cookies essenciais mantêm a Grafa funcionando bem. Alguns opcionais nos ajudam a ver o que está funcionando para melhorarmos. Você tem o controle — pode mudar de ideia quando quiser. Política de cookies · Política de privacidade